Design & Stress-Test · Gretel
turned synthetic data into a strategic-growth capability (finance; non-pharma) — referenced on Gretel's finance solutions page, dedicated case-study URL not directly resolved in this pass.
Gretel is a synthetic-data generation platform (acquired by NVIDIA) used to create privacy-preserving stand-ins for sensitive genomic and patient data.
This sits in the Design & Stress-Test stage of the AI use-case lifecycle: Named examples from the tools pharma teams use to scope, prototype and benchmark an AI use case before committing to build it — data-catalog, sandbox and evaluation platforms.
Source
Published by Gretel on its own site, referenced in Gretel’s own case-study library without a standalone URL.
More like this
Related use cases
- 01used Gretel's synthetic-data platform to create safe synthetic genomic datasets, enabling genomics research and safe/private data sharing between researchers, healthcare providers and industry
- 02generated 16M+ synthetic patient records for labor-and-delivery data to train ML forecasting models while preserving privacy
- 03synthetic time-series data for cross-institution use (finance; non-pharma) — referenced on Gretel's finance solutions page, dedicated case-study URL not directly resolved in this pass.
- 04pharmaceutical company using Agent Bricks for clinical and pharmacovigilance workflows
- 05runs its platform on Databricks/AWS to accelerate drug discovery; the Regeneron Genetics Center built one of the largest genetics databases pairing sequenced exomes with EHRs for 400,000+ people
- 06built a knowledge graph and recommendation engine on Databricks to help scientists mine millions of data points across thousands of sources and generate novel drug-target hypotheses; separately used Agent Bricks to parse 400,000+ clinical trial documents into structured data in under 60 minutes with no code